Psychedelics · FDPS explainer

Arguments against psychedelic legalization

Psilocybin, MDMA, LSD and ibogaine are being sold as medicine before any of them has passed the test every other medicine passes. The evidence, the harms and the money, with sources.

0psychedelics approved by the FDA to treat any conditionSAMHSA, 2026
10 to 1FDA advisers’ vote against MDMA therapy for PTSDFDA advisory committee, 2024
41%rise in teen hallucinogen use disorder in one yearNSDUH 2024
56%of Massachusetts voters rejected psychedelic legalizationBallotpedia, 2024

The case for psychedelics is made by investors, influencers and ballot campaigns. The case against is made by the trial data, the FDA’s own reviewers, poison centers and the parents who have buried children. The Foundation for Drug Policy Solutions laid out the second case here, with a link behind every claim.

Every figure links to its source. Updated as the FDA process, state law and the research change.

The short version
  1. No psychedelic is FDA-approved; the one that reached a decision was rejected 10 to 1.
  2. The trials are small and unblinded, and a fair comparison found no advantage over antidepressants.
  3. Teen hallucinogen use disorder rose 41 percent in one year; adolescent psilocybin poisonings tripled.
  4. The harms are real: psychosis, bad trips, lasting perceptual damage, cardiac risk, deaths.
  5. Oregon and Colorado sell psilocybin in storefronts with no diagnosis or prescription.
  6. Washington is fast-tracking approval on a political timeline.
  7. The industry says it plainly: “Now it is all about commercialization.”
What the evidence shows

Drug by drug: Is psilocybin safe? · Ibogaine: what the evidence shows · MDMA therapy: what the FDA found. The bigger picture: the psychedelic hype vs. the evidence · who opposes psychedelic legalization · all FDPS psychedelics pages

Seven arguments against psychedelic legalization

Each one links to the trial record, the federal data or the on-the-record statement behind it.

1No psychedelic has passed the test every other medicine passes

No classic psychedelic is FDA-approved to treat any condition. The only one to reach a decision, MDMA therapy for PTSD, was rejected in 2024 after FDA advisers voted 10 to 1 that its benefits did not outweigh its risks.

The FDA’s rejection letter found “substantial concerns about the reliability of the safety data,” unreported adverse events at trial sites, no laboratory data from the Phase 3 studies, and no proof the effect lasted beyond 18 weeks. It recommended an independent audit of all study records, including recordings of the therapy sessions. The American Psychiatric Association found “inadequate scientific evidence for endorsing the use of psychedelics to treat any psychiatric disorder,” and SAMHSA wrote in 2026 that “the data to date does not establish efficacy at large.”

Sources: FDA complete response letter · SAMHSA, 2026 · TDR on the Lykos letter

Go deeper: The Drug Report’s psychedelics explainer

2The trials are small, unblinded and often uncontrolled

When researchers compared psychedelic therapy with ordinary antidepressants under equal blinding conditions, the psychedelics were no better.

Patients in psychedelic trials can tell whether they got the drug, which lets expectation do part of the work. A team from UCLA, Imperial College London and UCSF corrected for that and found psychedelic therapy “no more effective than open-label” antidepressants. A review of nearly 200 psilocybin studies found almost half had no control group and the median study had 22 participants. Even the authors of the most favorable 2026 LSD study wrote that it “does not demonstrate that LSD treats anxiety or depression.”

Sources: UCSF · Colorado Springs Gazette · TDR

3Teen hallucinogen addiction rose 41 percent in a single year

Hallucinogen use disorder among 12 to 17 year olds increased from 59,000 to 83,000 between 2023 and 2024, about one in five of the teens who used.

Normalization reaches kids first. Psilocybin poison center cases among adolescents more than tripled between 2018 and 2022, with three in four requiring medical attention, and a University of Colorado analysis found psilocybin calls involving children up 723 percent from 2019 to 2023. In October 2026 police raided seven Colorado Springs smoke shops selling psilocybin, THC and 7-OH and found a 16-year-old alone behind the counter.

Sources: NSDUH 2024 · J. Adolescent Health · TDR Friday Fact · TDR on the Colorado Springs raid

4The harms are real: psychosis, bad trips, lasting perceptual damage, cardiac risk

In survey research, 39 percent of psilocybin users rated the experience among the five most challenging of their lives, and 11 percent put themselves or others at risk of physical harm.

Psychedelics are contraindicated for anyone with a personal or family history of psychosis, which state storefront programs do not reliably screen for. Hallucinogen persisting perception disorder can return months or years after use. Ibogaine, promoted for addiction, carries documented cardiac deaths and is in no FDA trial. Repeated LSD exposure, including microdosing, may be associated with valvular heart disease through the same receptor that pulled fenfluramine off the market. A former Alaska Airlines pilot who tried to shut down a jet’s engines in flight had taken psilocybin two days earlier. At the FDA’s 2026 hearing, Susan Taymor Sagy told the agency: “My 21-year-old Shira died following psychedelic use.”

Sources: FDPS psychedelics one-pager · DEA · ABC News · TDR on the FDA hearing

5Legalization by ballot measure or statute is medicine by vote

Oregon and Colorado license psilocybin storefronts with no FDA approval, no prescription and no diagnosis. Colorado calls them “Natural Medicine Health Centers.”

Luke Niforatos of FDPS calls that name “a total misnomer. No scientists have cleared these products to be medicine. There’s no dosage.” Massachusetts voters rejected psychedelic legalization by 56 percent in 2024; twenty months later the state House passed a pilot program anyway, tucked into an economic development bill with no floor debate. Never before has the country handed the question of what counts as medicine to entrepreneurs and ballot campaigns.

Sources: Ballotpedia · TDR on the Massachusetts House · Niforatos on Colorado Public Radio

6Washington is fast-tracking approval on a political timeline

Executive Order 14401 directs the FDA to cut psychedelic drug review from 10 to 12 months to as little as one to two, and tells the DEA to open a Right to Try pathway for ibogaine.

The FDA has issued priority vouchers for psilocybin and methylone and says itself that a voucher “does not constitute an FDA determination of safety or effectiveness.” Its September 2026 public hearing took comment on how to deliver psychedelic therapy while declaring the safety and effectiveness of the drugs off the table. FDPS called the order one that “elevates politics and hype over sound science.”

Sources: Executive Order 14401 · FDA hearing notice · FDPS statement

7It is an industry, and the industry says so

“Psychedelics needed an evangelist ten years ago. Now it is all about commercialization.” Christian Angermayer, founder of Compass Pathways and ATAI Life Sciences, 2026.

The two companies have raised more than $1.5 billion. A 2025 investigation found a donor collective ran “a strategic campaign to shape public perception in favor of Lykos Therapeutics’ failed MDMA-assisted therapy application and demonize its critics,” and positioned veterans groups as an “insurance policy.” At the FDA hearing, one investor said disclosing his financial ties “would take me longer than my two minutes.” Dr. Kevin Sabet, who said he was “one of the few here without a financial interest,” asked for the ordinary standard: “Psychedelics should earn approval the way any other class of drug does: through science and trials, not politics or podcasters.”

Sources: TDR on Angermayer · Truthdig investigation · TDR on the FDA hearing

Not anti-research

What FDPS supports instead

FDPS is not against research. It is against pretending the research is finished. The position, in one sentence: build the evidence, the safeguards and the data before approval, not after, and do not let politics or hype rewrite the standard every other medicine has to meet.

Rigorous, controlled trials

Adequately powered, properly blinded studies with independent data audits, on the same standard as every other drug.

Approval first, then access

If a psychedelic earns FDA approval, deliver it through physicians with monitoring, credentialing and adverse-event reporting built in advance.

No medicine by ballot measure

No state storefronts with no diagnosis, no prescription and no federal oversight, and no pilot programs that override what voters decided.

Proven care for veterans now

People in crisis deserve treatments that work today, not to be test subjects for an industry’s timeline.

FDPS psychedelics policy · FDPS comments to the FDA (PDF) · The Drug Report’s psychedelics explainer

Common questions

Questions people ask

Are psychedelics safe?

Not in the way the marketing implies. In survey research 39 percent of psilocybin users rate the trip among the five most challenging experiences of their lives and 11 percent put themselves or others at risk of harm. Psychedelics can trigger psychosis in vulnerable people, cause perceptual disturbances that return months later, and, for ibogaine, cardiac deaths. Teen hallucinogen use disorder rose 41 percent in one year and adolescent psilocybin poisonings have more than tripled.

Has the FDA approved psilocybin or MDMA?

No. No classic psychedelic is FDA-approved for any condition. The FDA rejected MDMA-assisted therapy for PTSD in 2024 and asked for another Phase 3 trial. Priority review vouchers issued in 2026 shorten review time; the FDA says they are not a finding of safety or effectiveness.

Do psychedelics work for depression or PTSD?

The trials have not shown it. Under equal blinding conditions psychedelic therapy was no more effective than ordinary antidepressants, most studies are small, and many have no control group. SAMHSA concluded in 2026 that the data do not establish efficacy, dosing or long-term outcomes.

What are the arguments against psychedelic legalization?

No FDA approval; weak, unblinded trials; rising teen use disorder and poisonings; documented harms including psychosis and cardiac risk; medicine-by-ballot storefronts that skip diagnosis and prescription; a federal fast track driven by politics; and a commercial industry that says openly it is about commercialization. Each argument on this page links to its source.

Is FDPS against psychedelic research?

No. FDPS supports rigorous controlled trials and FDA approval on the same standard as every other drug. It opposes approval on a political timeline, legalization by ballot measure or statute, storefront sales with no medical oversight, and an industry writing its own rules.

Where are psychedelics legal?

Nowhere under federal law. Oregon licenses psilocybin service centers and Colorado licenses healing centers and has decriminalized possession under state law. Massachusetts voters rejected legalization in 2024. New Mexico created a medical psilocybin program by statute in 2025.

Our family of organizations